- Home
- NBRG vs MCRB Comparison
NBRG vs MCRB Comparison
Compare NBRG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.42
Company Overview
Basic Information| Metric | NBRG | MCRB |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 71.0M |
| IPO Year | 2026 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBRG | MCRB |
|---|---|---|
| Price | $9.96 | $5.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 5.4K | ★ 128.6K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $5.31 |
| 52 Week High | $9.99 | $29.98 |
Technical Indicators
Market Signals| Indicator | NBRG | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 32.19 |
| Support Level | $9.94 | $5.31 |
| Resistance Level | $9.99 | $9.53 |
| Average True Range (ATR) | 0.00 | 0.65 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 0.00 | 10.92 |
Price Performance
Historical Comparison NBRG
MCRB
About NBRG Newbridge Acquisition Limited Class A Ordinary Share
Newbridge Acquisition Ltd is a blank check company.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.